Compare PRM & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRM | CRNX |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.9B |
| IPO Year | N/A | 2018 |
| Metric | PRM | CRNX |
|---|---|---|
| Price | $24.33 | $36.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $25.50 | ★ $74.78 |
| AVG Volume (30 Days) | 1.0M | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,039,000.00 |
| Revenue This Year | $27.93 | $722.66 |
| Revenue Next Year | $7.10 | $183.79 |
| P/E Ratio | $51.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.76 | $24.10 |
| 52 Week High | $29.88 | $57.99 |
| Indicator | PRM | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 56.43 | 43.63 |
| Support Level | $20.55 | $33.23 |
| Resistance Level | $24.85 | $37.23 |
| Average True Range (ATR) | 0.91 | 1.69 |
| MACD | 0.25 | 0.28 |
| Stochastic Oscillator | 91.91 | 64.01 |
Perimeter Solutions Inc is a solutions provider for the Fire Safety and Specialty Products industries. The Company's products and operations are managed and reported in two operating segments. Its Fire Safety segment provides fire retardants and firefighting foams, as well as specialized equipment and services typically offered in conjunction with the Company's retardant and foam products. The Specialty Products segment includes operations that develop, produce and market products for non-fire safety markets. Specialty Products segment is Phosphorus Pentasulfide (P2S5) based lubricant additives. P2S5 is also used in pesticide and mining chemicals applications, and emerging electric battery technologies.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.